NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis → At first glance, this chart looks like nonsense… (From The TradingPub) (Ad) Free INMB Stock Alerts $10.30 +0.16 (+1.58%) (As of 01:04 PM ET) Add Compare Share Share Today's Range$9.88▼$10.4850-Day Range$8.37▼$14.0152-Week Range$6.50▼$14.74Volume60,146 shsAverage Volume96,052 shsMarket Capitalization$187.46 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get INmune Bio alerts: Email Address INmune Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside55.3% Upside$16.00 Price TargetShort InterestBearish13.03% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.09Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.79 out of 5 starsMedical Sector811th out of 909 stocksBiological Products, Except Diagnostic Industry143rd out of 156 stocks 3.5 Analyst's Opinion Consensus RatingINmune Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageINmune Bio has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.03% of the float of INmune Bio has been sold short.Short Interest Ratio / Days to CoverINmune Bio has a short interest ratio ("days to cover") of 17.7, which indicates bearish sentiment.Change versus previous monthShort interest in INmune Bio has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldINmune Bio does not currently pay a dividend.Dividend GrowthINmune Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INMB. Previous Next 1.7 News and Social Media Coverage News SentimentINmune Bio has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for INmune Bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for INMB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, INmune Bio insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.72% of the stock of INmune Bio is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of INmune Bio is -6.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of INmune Bio is -6.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioINmune Bio has a P/B Ratio of 4.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About INmune Bio Stock (NASDAQ:INMB)INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Read More INMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INMB Stock News HeadlinesApril 23, 2024 | globenewswire.comINmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayApril 22, 2024 | msn.comINmune Bio rises 2%, on $4.5M direct offeringApril 24, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.April 22, 2024 | finance.yahoo.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 22, 2024 | globenewswire.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 16, 2024 | americanbankingnews.comINmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short InterestApril 8, 2024 | finance.yahoo.comINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 8, 2024 | globenewswire.comINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 24, 2024 | WealthPress (Ad)The system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)April 1, 2024 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | finance.yahoo.comINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 30, 2024 | seekingalpha.comINmune Bio, Inc. (INMB) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comINmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical AdvancementsMarch 29, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateMarch 28, 2024 | globenewswire.comINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateMarch 26, 2024 | globenewswire.comINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28March 13, 2024 | globenewswire.comINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyMarch 6, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XProMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment DevelopmentsMarch 5, 2024 | globenewswire.comINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™February 17, 2024 | finance.yahoo.comINMB Jun 2024 25.000 callFebruary 16, 2024 | finance.yahoo.comINMB Mar 2024 20.000 callFebruary 16, 2024 | finance.yahoo.comINMB Mar 2024 12.500 putFebruary 15, 2024 | finance.yahoo.comINMB Feb 2024 15.000 putFebruary 12, 2024 | finance.yahoo.comINmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 7, 2024 | finance.yahoo.comINmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024See More Headlines Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/24/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INMB CUSIPN/A CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+58.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,010,000.00 Net Margins-19,360.00% Pretax Margin-19,360.00% Return on Equity-64.11% Return on Assets-45.57% Debt Debt-to-Equity RatioN/A Current Ratio2.16 Quick Ratio2.16 Sales & Book Value Annual Sales$160,000.00 Price / Sales1,146.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book4.87Miscellaneous Outstanding Shares18,200,000Free Float11,632,000Market Cap$183.46 million OptionableOptionable Beta1.99 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Raymond Joseph Tesi M.D. (Age 68)Co-Founder, President, CEO, Chief Medical Officer & Chairman Comp: $500.5kMr. David J. Moss M.B.A. (Age 54)CFO, Treasurer & Secretary Comp: $394.9kDr. Mark William Lowdell BSc (Age 61)FRCPath, MICR, MSc, Ph.D., Chief Scientific Officer & Chief Manufacturing Officer Comp: $150.24kMr. Joshua S. Schoonover Esq.General CounselKey CompetitorsCardiff OncologyNASDAQ:CRDFAcumen PharmaceuticalsNASDAQ:ABOSInnate PharmaNASDAQ:IPHAKodiak SciencesNASDAQ:KODCandel TherapeuticsNASDAQ:CADLView All CompetitorsInsiders & InstitutionsWestside Investment Management Inc.Sold 7,475 shares on 4/19/2024Ownership: 0.189%Fermata Advisors LLCBought 2,025 shares on 4/12/2024Ownership: 0.174%Janney Montgomery Scott LLCSold 93,328 shares on 2/8/2024Ownership: 0.908%Financial Advocates Investment ManagementBought 990 shares on 2/8/2024Ownership: 0.069%Simplex Trading LLCSold 800 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions INMB Stock Analysis - Frequently Asked Questions Should I buy or sell INmune Bio stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INMB shares. View INMB analyst ratings or view top-rated stocks. What is INmune Bio's stock price target for 2024? 1 Wall Street research analysts have issued 12-month price objectives for INmune Bio's stock. Their INMB share price targets range from $16.00 to $16.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 55.3% from the stock's current price. View analysts price targets for INMB or view top-rated stocks among Wall Street analysts. How have INMB shares performed in 2024? INmune Bio's stock was trading at $11.26 at the beginning of 2024. Since then, INMB stock has decreased by 8.5% and is now trading at $10.30. View the best growth stocks for 2024 here. Are investors shorting INmune Bio? INmune Bio saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,530,000 shares, an increase of 6.3% from the March 15th total of 1,440,000 shares. Based on an average daily volume of 86,500 shares, the short-interest ratio is currently 17.7 days. Approximately 13.0% of the shares of the stock are short sold. View INmune Bio's Short Interest. When is INmune Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our INMB earnings forecast. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) released its quarterly earnings results on Thursday, March, 28th. The company reported ($0.47) earnings per share for the quarter. The firm earned $0.03 million during the quarter. INmune Bio had a negative trailing twelve-month return on equity of 64.11% and a negative net margin of 19,360.00%. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX). Who are INmune Bio's major shareholders? INmune Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Westside Investment Management Inc. (0.19%) and Fermata Advisors LLC (0.17%). Insiders that own company stock include David J Moss, Mark William Lowdell, Raymond Joseph Tesi, Scott Juda and Timothy J Schroeder. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INMB) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
